Omega Therapeutics elects Robert L. Rosiello to board as Class I director

Omega Therapeutics, Inc.

Rosiello appointed effective October 2, 2024; receives standard director compensation.
Annual retainer of $35,000 for board service under Non-Employee Director Compensation Program.
Initial option grant of 50,000 shares at $1.09 strike, vesting monthly over 3 years.
No arrangement or family relationship with other directors or officers; standard indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert L. Rosiello

Class I director

Omega Therapeutics, Inc.

Effective: 2024-10-02
Filed: October 4, 2024, 7:59 PM ET

On October 2, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”) elected Robert L. Rosiello as a Class I director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert L. Rosiello was elected as Class I director at Omega Therapeutics, Inc..

Action: elected
Role: Class I director

Exact text from the filing

On October 2, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”) elected Robert L. Rosiello as a Class I director of the Company, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-112962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.